Acomplia side effects, dosage, review, research studies, insomnia, depression, dry mouth and headaches

Patients taking the Sanofi-Aventis anti-obesity drug Acomplia, known generically as rimonabant, are likely to suffer Acomplia side effects such as depression and anxiety. Another Acomplia side effect is an increased amount of  suicidal thoughts. Acomplia -- also known by the brand name Zimulti in the United States -- is the first in a new class of weight loss pill drugs that switch off the same brain circuits that make people hungry when they smoke cannabis.
   A study in the British Medical Journal found that people taking Acomplia anti obesity drug would only see "modest" weight loss with many remaining significantly obese or overweight.

Opinion on the benefit and risk of Acomplia
Is rimonabant Acomplia efficacious and safe in the treatment of obesity?
Expert Opin Pharmacother. 2008 October. Doggrell SA. RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia.
This evaluation is of the Acopmlia Rimonabant in Obesity (RIO) programme of clinical trials, and of the first trial to determine whether rimonabant Acomplia has any effect on a clinical outcome. At present, it is doubtful whether the benefits of rimonabant outweigh the risks and side effects. Unless rimonabant is shown to have benefits in ongoing clinical outcome studies, there is little rationale to support its use in the treatment of obesity.

Acomplia side effects, caution, risks, danger
In November of 2007, Danish researchers reviewed four published studies featuring 4,100 patients and found that people taking Acomplia 20 milligrams per day were twice more likely to discontinue treatment due to depressive disorders and three times more likely to stop because of anxiety than those who received a placebo. In addition to depression and anxiety, Acomplia side effects include dry mouth and headaches.

Sleep problems with Acomplia
Sleep disorders associated with treatment with rimonabant
Rev Neurol. 2008 Oct 16-31;47(8):446. Sempere AP, Giner-Bernabeu JC, Berenguer-Ruiz L, Selles-Galiana MF, Hernandez-Rubio L, Lezcano-Rodas M. Sempere AP, Giner-Bernabeu JC, Berenguer-Ruiz L, Selles-Galiana MF, Hernandez-Rubio L, Lezcano-Rodas M.

Acomplia anti obesity pill - Sanofi-Aventis has seen strong demand for new obesity pill Acomplia since its launch in Britain in late June, 2006. Acomplia, which switches off brain circuits that make people hungry when they smoke cannabis, is viewed as Sanofi's most important new product, with potential annual sales global of more than $3 billion. As a treatment for obesity, the latest diet-aid drug, Acomplia, produces only moderate weight loss, according to a review of clinical trial results in October 2006. Acomplia, made by Sanofi-Aventis, is known generically as rimonabant. It was approved for use in the European Union earlier in 2006.
   Novermber 2006 - Sanofi-Aventis's new obesity pill Acomplia is selling well in Britain and Ireland. In Germany, however, insurers have dismissed Acomplia as a "lifestyle" treatment and are refusing reimbursement. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
   November 2006 - Acomplia (rimonabant) is approved in Mexico to treat obese/overweight patients with associated type 2 diabetes or dyslipidemia or to help them improve glycemic control on background of conventional antidiabetic treatment
   April 2008 - The Sanofi-Aventis weight loss drug rimonabant does not slow heart disease in obese patients with fat around the middle, and Acomplia side effects include anxiety and depression. More than 40 percent of patients who take Acomplia, develop psychiatric side effects.

A supplement with herbs as an excellent alternative to anti obesity medications is a doctor formulated product called Diet Rx.